The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

For patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) with a contraindication for cis ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.

If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...

Lenalidomide improved upon the efficacy of durvalumab in patients with refractory or advanced CTCL in a phase 1/2 trial.

Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...

The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...

Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.

The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...

Rucaparib Maintenance Improves Long-Term Outcomes in Ovarian Cancer Rucaparib maintenance after first-line chemotherapy and ...